GlassScriptPhysician profile
Hoon K Lee
NPI 1255318689
$1,241.51
in general payments reported to CMS, 2019-2025
24 companies · $16.91 in 2025
The $16.91 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $271 · 2021: $15.52 · 2022: $53.26 · 2023: $623 · 2024: $122 · 2025: $16.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $197.09 | 2020-2023 | Keytruda, Lynparza |
| Tactile Systems Technology INC | $165.89 | 2019-2023 | Entre Plus, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $128.18 | 2019-2024 | |
| Novocure INC. | $87.30 | 2019-2023 | Optune |
| Astrazeneca Pharmaceuticals LP | $74.33 | 2019-2023 | Enhertu |
| Amgen INC. | $73.08 | 2020 | |
| Janssen Biotech, INC. | $62.32 | 2020-2023 | Tecvayli, Darzalex, Stelara |
| Glaxosmithkline, LLC. | $59.25 | 2023-2024 | Jemperli, Zejula |
| Incyte Corporation | $48.35 | 2023-2024 | Jakafi |
| Lilly USA, LLC | $43.38 | 2023 | Retevmo, Jaypirca, Verzenio |
| Emd Serono, INC. | $38.95 | 2023 | Tepmetko |
| Genmab U.S., INC. | $31.64 | 2024 | Tivdak |
| Boston Scientific Corporation | $29.02 | 2022-2025 | Spaceoar System |
| Stemline Therapeutics INC. | $24.28 | 2023 | Orserdu |
| Puma Biotechnology, INC. | $23.08 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.86 | 2020 | |
| Daiichi Sankyo INC. | $22.02 | 2023 | Enhertu |
| G1 Therapeutics, INC. | $21.11 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $19.11 | 2023 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2024 | Alunbrig |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2020 | |
| Qfix | $13.50 | 2023 | |
| Rigel Pharmaceuticals, INC. | $12.97 | 2020 | |
| Blue Earth Diagnostics | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.